Patent ID: 11913078
Assignee: MYRIAD INTERNATIONAL GMBH
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 18:
19. A method of analyzing a tumor sample from a patient with an estrogen receptor positive and HER2 negative breast tumor, comprising:
(a) obtaining a tumor sample from a patient with an estrogen receptor positive and HER2 negative breast tumor;
(b) extracting RNA from the sample;
(c) amplifying a set of marker genes in the RNA, the set of marker genes consisting of AURKA and at least two of the following genes: BIRCS, PVALB, NMU, STC2, RBBP8, PTGER3, CXCL12, CDH1, and PIP;
(d) determining the RNA expression levels of the set of marker genes; and
(e) analyzing the expression levels of the set of marker genes by combining the expression levels to yield a test combined score that is indicative of responsiveness to cytotoxic chemotherapy, wherein the tumor is responsive to a cytotoxic chemotherapy if the test combined score exceeds a reference combined score and the tumor is non-responsive to a cytotoxic therapy if the test combined score does not exceed the reference combined score.